The decision to allow a new trial could have  implications for both the companies and families with babies born prematurely.

Abbott (ABT) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near term. Over the past ...

Key Takeaways Infant formula makers Abbott and Reckitt saw their stocks decline Friday after a judge ruled plaintiffs could ...

Missouri 22nd Judicial Circuit Court Judge Michael Noble granted the plaintiff's motion for a new trial on Thursday, citing ...

Abbott Laboratories and Reckitt Benckiser Group Plc shares fell as a judge ordered a new trial after rejecting a verdict that ...

The Department of Health and Human Services and the Food and Drug Administration, launched a new initiative to ensure infant ...

Back in October, a jury found North Chicago-based Abbott and Reckitt’s formula subsidiary Mead Johnson not responsible for a ...

Health and Human Services Secretary Robert F. Kennedy Jr. is planning to meet Tuesday with executives of companies that make ...

The FDA would embark on a comprehensive look at the nutrients used in infant formula and increase testing for heavy metals ...

Shares of Abbott Laboratories and Reckitt Benckiser fell Friday after a judge ruled a new trial could be heard involving a case on their infant formula products that had already seen a ruling in their ...

We recently published a list of Friday’s 10 Worst Performing Stocks. In this article, we are going to take a look at where ...

Juries in the first two cases ruled against the formula makers, delivering verdicts of $495 million against Abbott Laboratories and $60 million against Mead Johnson. The case that wrapped up in ...